Wednesday February 7, 10:08 am Eastern Time
Press Release
Xechem Announces Issuance of a Broad U.S. Patent No. 6,177,456 For New Second Generation Paclitaxel
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb. 7, 2001--Xechem International, Inc. (OTC BB ZKEM) today announced that the U.S. Patent & Trademark Office has issued US Patent No. 6,177,456, January 23, 2001 containing broad claims to novel second generation paclitaxel analogs developed at Xechem's New Brunswick Laboratories.
Preliminary studies show antineoplastic efficacy of the new, novel analogs against a wide array of cancer tumor cells.
The new second generation paclitaxel analog patent covers several compounds, pharmaceutical formulations comprising the compounds, a method for administering such compounds for treating both animal and human tumors, and methods for production of the compounds.
According to Xechem's President & CEO, Dr. Ramesh Pandey, ``We are excited about the issuance of the new U.S. Patents for Xechem's growing portfolio of promising and innovative new paclitaxel analogs and paclitaxel formulations which are strategically poised to become a major presence in this important industry. With the exclusivity afforded by the various issued patents for second generation paclitaxel, we hope to develop unique new products of choice in this important and burgeoning area for patients in need of alternatives to conventional chemotherapy treatment. With the recent FDA approval of generic entry into the paclitaxel market, Xechem is also working on an Abbreviated New Drug Application (ANDA) for generic paclitaxel for submission to the US FDA in the next few months.''
Xechem International of New Brunswick, NJ, with subsidiary companies in USA, India and joint venture partners in both Hong Kong and Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary pharmaceuticals from natural sources, specializing in the development of niche, generic, difficult to replicate anticancer, antiviral (including Human Immuno-deficiency Virus, HIV) and antifungal compounds. The Company also screens extracts and pure compounds from China and India for their therapeutic use.
XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products as GinkgoOnce®, GinsengOnce®, GarlicOnce®, Gugulon(TM), and Co-Enzyme Q-10 and numerous products, which are under development. (www.xetapharm.com)
This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.
This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Xechem International, New Brunswick
Dr. Ramesh C. Pandey
President and Chief Executive Officer
732/247-3300
All day long, they lie in the sun, and when the sun goes down, they lie some more.
